Featured Research

from universities, journals, and other organizations

Heparin derivative suppresses neuroblastoma tumor growth

Date:
June 17, 2014
Source:
Duke Medicine
Summary:
A new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming, has been discovered by researchers. The study, conducted in mice, found that when heparin is altered to remove its blood-thinning properties, it can suppress and shrink neuroblastoma tumors without causing severe bleeding.

Researchers at Duke Medicine have identified a new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming.

Related Articles


The study, conducted in mice and published June 17, 2014, in the Journal of Clinical Investigation, found that when heparin is altered to remove its blood-thinning properties, it can suppress and shrink neuroblastoma tumors without causing severe bleeding.

"Our research translates mechanistic insights about heparin into a potential new therapy for neuroblastoma, and possibly other cancers," said senior author Gerard C. Blobe, M.D., Ph.D., professor of medicine, pharmacology and cancer biology at Duke.

Neuroblastoma is a cancer that arises in nerve tissue, and is typically seen in infants and children. While neuroblastoma is rare overall -- 700 new cases in the United States each year, according to the American Cancer Society -- it is the most common cancer in infants.

Despite numerous treatment options for neuroblastoma, survival rates in children with advanced cancer are less than 40 percent due to disease recurrence and the persistence of residual cancerous cells after chemotherapy. However, one difference between neuroblastoma and other solid tumors is the function of the stroma, or connective tissue around the tumor.

"Most of the time we think of stroma in solid tumors as a bad thing that helps cancers become more invasive. In neuroblastoma, it's the opposite: having a lot of connective tissue around the tumor does something favorable for patients," Blobe said.

Studying the stroma's biology, the researchers determined that the connective tissue produces and releases receptors involved in nervous system signaling called heparan sulfate proteoglycans. The heparan sulfate proteoglycans had a differentiating effect on the cancer cells, making immature cancer cells act more like mature neurons and keeping them from proliferating.

Heparan sulfate proteoglycans are structurally similar to the anticoagulant heparin, which led the researchers to hypothesize that heparin might recreate the function naturally occurring in the stroma. They administered heparin to human neuroblastoma cells in laboratory cultures as well as to mice with neuroblastoma, and found that it could differentiate cancer cells and cause tumors to regress in mice. However, the heparin caused severe bleeding, rendering it an unusable treatment.

"That's what caused the 'eureka' moment. Heparin was effective, but caused serious bleeding," said Erik H. Knelson, an M.D./Ph.D. candidate at Duke University School of Medicine and the study's lead author. "If we could find a modified heparin that still promoted differentiation but did not cause anticoagulation, we might have a successful treatment."

The researchers studied the structure of heparin, and determined that although certain properties were necessary for anticoagulation, only some were important for the signaling that promoted differentiation. Using this finding, they identified a derivative of heparin that would still allow for differentiation but not cause anticoagulation.

When tested in lab cultures, the heparin derivative suppressed neuroblastoma growth. In mice, it slowed the cancer's progression, shrunk the tumors and extended the animals' lives.

"The study illustrates the benefit of listening to the cancer and its biology," Knelson said. "We started out with an investigation of tumor stroma and its mechanism, and designed a potential therapy using this new understanding."

The team is now working to move the research into clinical trials in humans to determine whether the heparin derivative offers the same benefit in humans as it did in mice.

"We want to repurpose a drug that's already out there for the benefit of patients," Blobe said. "What's exciting about that is there are other tumors in which differentiation is useful, so there's the potential to apply these insights to other cancers."


Story Source:

The above story is based on materials provided by Duke Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Erik H. Knelson, Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, Gerard C. Blobe. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. Journal of Clinical Investigation, 2014; DOI: 10.1172/JCI74270

Cite This Page:

Duke Medicine. "Heparin derivative suppresses neuroblastoma tumor growth." ScienceDaily. ScienceDaily, 17 June 2014. <www.sciencedaily.com/releases/2014/06/140617130758.htm>.
Duke Medicine. (2014, June 17). Heparin derivative suppresses neuroblastoma tumor growth. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2014/06/140617130758.htm
Duke Medicine. "Heparin derivative suppresses neuroblastoma tumor growth." ScienceDaily. www.sciencedaily.com/releases/2014/06/140617130758.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins